A型肉毒素治疗唾液腺非肿瘤性疾病研究进展

doi:10.19438/j.cjoms.2022.06.016

摘要/Abstract

摘要： A型肉毒毒素（botulinum toxin A,BTX-A）是一种神经毒性蛋白,可抑制乙酰胆碱释放,从而阻断胆碱能受体的信号传导。BTX-A注射治疗已被广泛用于多个领域。近年来,BTX-A的应用价值及适应证不断被发掘与拓展,越来越多的研究关注其在唾液腺相关疾病的治疗应用,如用于治疗流涎症、涎瘘、囊肿等。本文综述了近年来国内外BTX-A用于治疗包括各类唾液腺非肿瘤疾病的相关文献,对治疗用量、注射方法、治疗效果等进行总结与探讨,以期为国内推广应用BTX-A局部注射治疗流涎症、涎瘘、慢性阻塞性腮腺炎提供参考与指导。

关键词: 慢性阻塞性腮腺炎, A型肉毒素, 流涎症, 涎瘘

Abstract: Botulinum toxin A (BTX-A) is a neurotoxic protein that inhibits the release of acetylcholine and blocks cholinergic receptor signaling. BTX-A therapy has been widely used in many fields. In recent years, the application value and indications of BTX-A have been continuously explored and expanded, and more and more studies have focused on its application in the treatment of salivary gland-related diseases, such as sialorrhea, salivary fistula, salivary gland cyst, Frey's syndrome et al. In this paper, the literature on the use of BTX-A in the treatment of non-neoplastic salivary gland diseases including chronic obstructive parotitis in recent years was reviewed, and the treatment dosage, injection method and treatment effect were summarized and discussed, in order to provide reference and guidance for the clinical application in the treatment of chronic obstructive parotitis, sialorrhea and salivary fistula.

Key words: Chronic obstructive parotitis, Botulinum toxin A, Sialorrhea, Salivary fistula

中图分类号:

R781.7

黄建湖, 赵恒帅, 韦江平. A型肉毒素治疗唾液腺非肿瘤性疾病研究进展[J]. 中国口腔颌面外科杂志, 2022, 20(6): 607-611.

HUANG Jian-hu, ZHAO Heng-shuai, WEI Jiang-ping. Progress of botulinum toxin type A in the treatment of non-neoplastic salivary gland disease[J]. China J Oral Maxillofac Surg, 2022, 20(6): 607-611.

参考文献

[1] Xu H, Shan XF, Cong X, et al.Pre- and post-synaptic effects of botulinum toxin A on submandibular glands[J]. J Dent Res, 2015, 94(10): 1454-1462.
[2] Bushara KO.Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands[J]. Med Hypotheses, 1997, 48(4): 337-339.
[3] Lovato A, Restivo DA, Ottaviano G, et al.Botulinum toxin therapy: functional silencing of salivary disorders[J]. Acta Otorhinolaryngol Ital, 2017, 37(2): 168-171.
[4] Koch M, Kunzel J, Iro H, et al.Long-term results and subjective outcome after gland-preserving treatment in parotid duct stenosis[J]. Laryngoscope, 2014, 124(8): 1813-1818.
[5] Delagnes EA, Aubin-Pouliot A, Zheng M, et al.Sialadenitis without sialolithiasis: prospective outcomes after sialendoscopy-assisted salivary duct surgery[J]. Laryngoscope, 2017, 127(5): 1073-1079.
[6] Delagnes EA, Zheng M, Aubin-Pouliot A, et al.Salivary duct stenosis: short-term symptom outcomes after sialendoscopy-assisted salivary duct surgery[J]. Laryngoscope, 2017, 127(12): 2770-2776.
[7] Strohl MP, Chang CF, Ryan WR, et al.Botulinum toxin for chronic parotid sialadenitis: a case series and systematic review[J]. Laryngoscope Investig Otolaryngol, 2021, 6(3): 404-413.
[8] Marina MB, Sani A, Hamzaini AH, et al.Ultrasound-guided botulinum toxin A injection: an alternative treatment for dribbling[J]. J Laryngol Otol, 2008, 122(6): 609-614.
[9] Jost WH, Baumer T, Laskawi R, et al.Therapy of sialorrhea with botulinum neurotoxin[J]. Neurol Ther, 2019, 8(2): 273-288.
[10] Csüry TD, Mansour N, Becker C, et al.Botulinum neurotoxin therapy of the major salivary glands in chronic sialorrhea[J]. Laryngorhinootologie, 2022, 101(3): 193-194.
[11] Jost WH, Friedman A, Michel O, et al.SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea[J]. Neurology, 2019, 92(17): e1982-e1991.
[12] Berweck S, Bonikowski M, Kim H, et al.Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI[J]. Neurology, 2021, 97(14): e1425-e1436.
[13] Dashtipour K, Bhidayasiri R, Chen JJ, et al.RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials[J]. J Clin Mov Disord, 2017, 4: 9-17.
[14] George KS, Kiani H, Witherow H.Effectiveness of botulinum toxin B in the treatment of drooling[J]. Br J Oral Maxillofac Surg, 2013, 51(8): 783-785.
[15] Lee YC, Park GC, Lee JW, et al.Prevalence and risk factors of sialocele formation after partial superficial parotidectomy: amulti-institutional analysis of 357 consecutive patients[J]. Head Neck, 2016, 38(Suppl 1): E941-E944.
[16] Guntinas-Lichius O, Sittel C.Treatment of postparotidectomy salivary fistula with botulinum toxin[J]. Ann Otol Rhinol Laryngol, 2001, 110(12): 1162-1164.
[17] Chow TL, Kwok SP.Use of botulinum toxin type A in a case of persistent parotid sialocele[J]. Hong Kong Med J, 2003, 9(4): 293-294.
[18] Marchese-Ragona R, Marioni G, Restivo DA, et al.The role of botulinum toxin in postparotidectomy fistula treatment. a technical note[J]. Am J Otolaryngol, 2006, 27(3): 221-224.
[19] Arnaud S, Batifol D, Goudot P, et al.Nonsurgical management of traumatic injuries of the parotid gland and duct using type A botulinum toxin[J]. Plast Reconstr Surg, 2006, 117(7): 2426-2430.
[20] Hill SE, Mortimer NJ, Hitchcock B, et al.Parotid fistula complicating surgical excision of a basal cell carcinoma: successful treatment with botulinum toxin type A[J]. Dermatol Surg, 2007, 33(11): 1365-1367.
[21] Hatzis GP, Finn R.Using botox to treat a mohs defect repair complicated by a parotid fistula[J]. J Oral Maxillofac Surg, 2007, 65(11): 2357-2360.
[22] Ihler F, Laskawi R, Matthias C, et al.Botulinum toxin a after microvascular ALT flap in a patient with (corrected) squamous cell carcinoma of the tongue[J]. HNO, 2012, 60(6): 524-527.
[23] Laskawi R, Winterhoff J, Köhler S, et al.Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results[J]. Oral Maxillofac Surg, 2013, 17(4): 281-285.
[24] Gok G, Michl P, Williams MD, et al.Ultrasound-guided botulinum toxin injection to treat a parotid fistula following gunshot injury[J]. J R Army Med Corps, 2015, 161(1): 64-66.
[25] Melville JC, Stackowicz DJ, Jundt JS, et al.Use of botox (onabotulinumtoxina) for the treatment of parotid sialocele and fistula after extirpation of buccal squamous cell carcinoma with immediate reconstruction using microvascular free flap: a report of 3 cases[J]. J Oral Maxillofac Surg, 2016, 74(8): 1678-1686.
[26] Ferron C, Cernea SS, Almeida ART, et al.Primary treatment of early fistula of parotid duct with botulinum toxin type A injection[J]. An Bras Dermatol, 2017, 92(6): 864-866.
[27] Send T, Bertlich M, Eichhorn KW, et al.Management and follow-up results of salivary fistulas treated with botulinum toxin[J]. Laryngoscope, 2019, 129(2): 403-408.
[28] Graillon N, Le Roux MK, Chossegros C, et al.Botulinum toxin for ductal stenosis and fistulas of the main salivary glands[J]. Int J Oral Maxillofac Surg, 2019, 48(11): 1411-1414.
[29] Costan VV, Dabija MG, Ciofu ML, et al.A functional approach to posttraumatic salivary fistula treatment: the use of botulinum toxin[J]. J Craniofac Surg, 2019, 30(3): 871-875.
[30] Maharaj S, Mungul S, Laher A.Botulinum toxin A is an effective therapeutic tool for the management of parotid sialocele and fistula: a systematic review[J]. Laryngoscope Investig Otolaryngol, 2020, 5(1): 37-45.
[31] Guntinas-Lichius O, Jungehülsing M.Treatment of chronic parotid sialectasis with botulinum toxin A[J]. Laryngoscope, 2002, 112(3): 586-587.
[32] Ellies M, Gottstein U, Rohrbach-Volland S, et al.Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis[J]. Laryngoscope, 2004, 114(10): 1856-1860.
[33] Capaccio P, Torretta S, Osio M, et al.Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders[J]. Am J Otolaryngol, 2008, 29(5): 333-338.
[34] Kruegel J, Winterhoff J, Koehler S, et al.Botulinum toxin: a noninvasive option for the symptomatic treatment of salivary gland stenosis - a case report[J]. Head Neck, 2010, 32(7): 959-963.
[35] Daniel SJ, Diamond M.Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjögren syndrome[J]. Otolaryngol Head Neck Surg, 2011, 145(1): 180-181.
[36] Reddy R, White DR, Gillespie MB.Obstructive parotitis secondary to an acute masseteric bend[J]. ORL J Otorhinolaryngol Relat Spec, 2012, 74(1): 12-15.
[37] O'Neil LM, Palme CE, Riffat F, et al. Botulinum toxin for the management of Sjögren syndrome-associated recurrent parotitis[J]. J Oral Maxillofac Surg, 2016, 74(12): 2428-2430.
[38] El Khoury J, Haber E, Nasr M,et al.Botulinum neurotoxin A for parotid enlargement in cystic fibrosis: the first case report[J]. J Oral Maxillofac Surg, 2016, 74(9):1771-1773.
[39] Trapeau C, Foletti JM, Collet C, et al.Clinical efficacy of botulinum toxin in salivary duct stenosis: a preliminary study of six cases[J]. J Stomatol Oral Maxillofac Surg, 2017, 118(6): 349-352.
[40] Kwon SY, Chun KJ, Kil HK, et al.Botulinum toxin injection for chronic parotitis: a multi-center and prospective trial[J]. Laryngoscope, 2021, 131(6): E1903-E1909.
[41] Schwalje AT, Hoffman HT.Intraductal salivary gland infusion with botulinum toxin[J]. Laryngoscope Investig Otolaryngol, 2019, 4(5): 520-525.